For the second time, the Federal Trade Commission has filed a lawsuit alleging Endo International (ENDP) and Impax Laboratories violated antitrust laws by striking a deal that sought to eliminate competition for an opioid painkiller.

In filing its suit, the FTC pointed to a request made in 2017 by the Food and Drug Administration for Endo to voluntarily withdraw its reformulated version of the drug, which was called Opana ER, or extended release. The FDA took this step — a highly unusual move at the time — over concerns the drug was too easily abused. An FDA advisory panel had already recommended the drug should be withdrawn.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]